Does Mounjaro make you sad? This question concerns many patients starting tirzepatide treatment for type 2 diabetes or weight management in the UK. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA, with common side effects primarily affecting the gastrointestinal system. Whilst anecdotal reports mention mood changes, there is currently no established causal link between Mounjaro and depression in official prescribing information or NICE guidance. This article examines the available evidence, explores potential mechanisms that might influence mood during treatment, and provides practical guidance for patients experiencing emotional changes whilst taking this medication.

Does Mounjaro Make You Sad? Understanding the Connection

Mounjaro (tirzepatide) is a prescription medicine licensed in the UK for the treatment of type 2 diabetes. In the UK, tirzepatide for weight management is authorised under a separate product brand for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related health condition. As with any medication, patients and healthcare professionals are naturally concerned about potential side effects, including those affecting mental health and mood.

The question of whether Mounjaro can make you feel sad or contribute to low mood is one that has emerged as more people begin treatment with this medication. Tirzepatide is a dual GIP/GLP-1 receptor agonist single molecule that works on two distinct hormone pathways. Whilst the most commonly reported side effects of Mounjaro relate to the gastrointestinal system—such as nausea, vomiting, diarrhoea, and constipation—there have been anecdotal reports and patient concerns regarding mood changes, including feelings of sadness or depression.

It is important to note that there is currently no established causal link between Mounjaro and depression or persistent low mood in the official prescribing information approved by the MHRA (Medicines and Healthcare products Regulatory Agency) or guidance from NICE (National Institute for Health and Care Excellence). This is consistent with the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) review, which found no causal association between GLP-1 receptor agonists and suicidal thoughts or self-harm.

This article examines the available evidence, explores potential mechanisms that might influence mood during Mounjaro treatment, and provides practical guidance for patients who experience emotional changes whilst taking this medication. Understanding these connections empowers patients to make informed decisions and seek appropriate support when needed.

Reported Mood Changes and Depression with Mounjaro

Clinical trials of Mounjaro have primarily focused on glycaemic control and weight loss outcomes, with comprehensive monitoring of physical side effects. Mood disturbances, including depression and anxiety, were not highlighted as common adverse reactions in the pivotal SURPASS trials that led to the drug's approval. The Summary of Product Characteristics (SmPC) for Mounjaro does not list depression or mood changes as recognised side effects at present.

However, post-marketing surveillance and patient forums have documented individual reports of mood changes, including:

• Feelings of sadness or tearfulness without clear external triggers

• Reduced motivation or interest in previously enjoyable activities

• Increased anxiety or emotional sensitivity

• Irritability or mood swings

It is crucial to distinguish between correlation and causation. Many factors may contribute to mood changes during Mounjaro treatment, including:

Rapid weight loss and metabolic changes: Significant caloric restriction and rapid weight reduction may potentially affect energy levels and various physiological processes, which some patients report as influencing their mood, though the exact mechanisms require further research.

Pre-existing mental health conditions: Individuals with type 2 diabetes or obesity have higher rates of depression and anxiety compared to the general population. These conditions may become more apparent or worsen independently of medication use.

Physical side effects: Persistent nausea, fatigue, or gastrointestinal discomfort can understandably affect quality of life and emotional wellbeing, leading to feelings of low mood or frustration.

Blood glucose fluctuations: While uncommon with tirzepatide alone, hypoglycaemia (low blood sugar) can occur, particularly when combined with insulin or sulfonylureas. Low blood glucose can cause irritability, anxiety, and mood changes that might be mistaken for depression.

Lifestyle and social factors: Changes in eating patterns, social situations involving food, and the psychological adjustment to weight loss can all impact mental health.

The MHRA continues to monitor the safety profile of all medications through the Yellow Card scheme. Both patients and healthcare professionals are encouraged to report any suspected adverse reactions, including mood changes, via yellowcard.mhra.gov.uk or the Yellow Card app to contribute to ongoing pharmacovigilance.

What to Do If You Feel Low While Taking Mounjaro

If you experience persistent feelings of sadness, low mood, or symptoms of depression whilst taking Mounjaro, it is essential to take these symptoms seriously and seek appropriate support. Do not simply discontinue the medication without medical guidance, as abrupt cessation may affect your diabetes control or weight management plan.

Immediate steps to consider:

• Contact your GP or prescribing clinician to discuss your symptoms. Be specific about when the mood changes began, their severity, and any other factors that may be relevant (such as life stressors, sleep disturbances, or other medications).

• Keep a symptom diary documenting your mood, energy levels, sleep patterns, and any physical symptoms. This information helps healthcare professionals assess whether there may be a connection to your medication or other contributing factors.

• Assess for other causes: Your doctor may wish to investigate other potential explanations for low mood, such as thyroid function, vitamin levels (particularly B12 and vitamin D), anaemia, or other factors that can occur with significant weight loss.

• Monitor for hypoglycaemia: If you're also taking insulin or sulfonylureas, discuss with your healthcare team whether low blood glucose episodes might be contributing to mood changes and whether dose adjustments are needed.

When to seek urgent help:

If you experience thoughts of self-harm, suicidal ideation, or severe depression, contact your GP immediately, call NHS 111, or go to your local A&E department. In an emergency or if you cannot keep yourself safe, call 999. You can also contact the Samaritans on 116 123 (available 24 hours a day).

Management options your healthcare team may consider:

• Dose adjustment: Reducing the dose of Mounjaro temporarily or slowing the titration schedule may help if side effects are contributing to mood disturbance.

• Medication review: Assessing all current medications for potential interactions or cumulative effects on mood.

• Referral to mental health services: If depression or anxiety is significant, referral to NHS Talking Therapies (which you can self-refer to in many areas) or consideration of antidepressant medication may be appropriate.

• Nutritional support: Ensuring adequate caloric intake and balanced nutrition during weight loss, possibly with dietitian input, to support both physical and mental health.

Your mental health is as important as your physical health, and effective treatments are available for depression and anxiety. Open communication with your healthcare team ensures you receive comprehensive, individualised care.

How Mounjaro Works and Its Effects on Mood

Understanding the mechanism of action of Mounjaro provides context for considering potential effects on mood and emotional wellbeing. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This means it activates two distinct receptor systems involved in glucose metabolism and appetite regulation.

Pharmacological actions include:

• Enhanced insulin secretion in response to elevated blood glucose levels

• Suppression of glucagon release, reducing hepatic glucose production

• Delayed gastric emptying, which prolongs satiety and reduces appetite

• Effects on brain appetite centres, particularly in the hypothalamus

These mechanisms lead to improved glycaemic control in type 2 diabetes and significant weight loss. In the SURMOUNT-1 trial, which studied tirzepatide specifically in people with obesity without diabetes at higher doses (5-15mg), participants lost approximately 15-20% of body weight over 72 weeks. Weight loss results may differ in people with type 2 diabetes and at different doses.

Potential pathways that might affect mood:

Whilst there is no direct evidence that tirzepatide alters mood-regulating neurotransmitters such as serotonin or dopamine, several indirect mechanisms have been hypothesised:

Neurological considerations: GLP-1 receptors are present in various brain regions, including areas involved in reward processing and emotional regulation. The extent to which tirzepatide crosses the blood-brain barrier and its effects on central nervous system function remain areas of ongoing research.

Metabolic changes: Rapid weight loss affects various physiological processes. The relationship between these changes and mood requires further investigation.

Nutritional factors: Reduced food intake and altered eating patterns may lead to inadequate intake of nutrients important for mental health, including omega-3 fatty acids, B vitamins, and amino acids required for neurotransmitter synthesis.

Blood glucose fluctuations: Although Mounjaro improves overall glycaemic control, some patients may experience periods of lower blood glucose, particularly if also taking insulin or sulfonylureas, which can manifest as mood changes, irritability, or anxiety.

Some preliminary research on GLP-1 receptor agonists has suggested potential neuroprotective effects in laboratory and animal studies, though this remains investigational and has not been established for tirzepatide in humans. The relationship between these medications and brain function is complex and not fully understood. Ongoing post-marketing surveillance and real-world evidence will continue to inform our understanding of Mounjaro's safety profile, including any potential effects on mental health and emotional wellbeing.

Frequently Asked Questions